Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes
More topics under "A61K - Preparations for medical, dental, or toilet purposes" (2,585,043)
A61K 101 - Radioactive non-metals (526)
A61K 103 - Radioactive metals (481)
A61K 125 - Containing or obtained from roots, bulbs, tubers, corms or rhizomes (2,645)
A61K 127 - Containing or obtained from leaves (1,806)
A61K 129 - Containing or obtained from bark (325)
A61K 131 - Containing or obtained from seeds, nuts, fruits or grains (1,932)
A61K 133 - Containing or obtained from flowers or blossoms (665)
A61K 135 - Containing or obtained from stems, stalks, branches, twigs or shoots (756)
A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
A61K 33 - Medicinal preparations containing inorganic active ingredients (56,213)
A61K 35 - Medicinal preparations containing material or reaction products thereof with undetermined constitution (125,838)
A61K 36 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines (179,316)
A61K 38 - Medicinal preparations containing peptides (316,240)
A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
A61K 41 - Medicinal preparations obtained by treating materials with wave energy or particle radiation (9,445)
A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964)
A61K 49 - Preparations for testing in vivo (35,376)
A61K 50 - Electrically conductive preparations for use in therapy or testing in vivo, e.g. conductive adhesives or gels to be used with electrodes for electrocardiography (ecg) or for transcutaneous drug administration (62)
A61K 51 - Preparations containing radioactive substances for use in therapy or testing in vivo (24,291)
A61K 6 - Preparations for dentistry (18,259)
A61K 8 - Cosmetics or similar toilet preparations (170,551)
A61K 9 - Medicinal preparations characterised by special physical form (299,044)
Patents for A61K - Preparations for medical, dental, or toilet purposes (29,449)
03/2005
03/10/2005WO2004058190A3 Methods for treating taxol-induced sensory neuropathy
03/10/2005US20050054720 Saururus cernuus compounds that inhibit cellular responses to hypoxia
03/10/2005US20050054708 Combinations of drugs for the treatment of neoplasms
03/10/2005US20050054659 Pyrazine modulators of cannabinoid receptors
03/10/2005US20050054646 Compositions of a cyclooxygenase-2 selective inhibitor and an antioxidant agent for the treatment of central nervous system disorders
03/10/2005US20050054644 Hydrolytically-resistant boron-containing therapeutics and methods of use
03/10/2005US20050054625 Method for treating diseases using HSP90-inhibiting agents in combination with nuclear export inhibitors
03/10/2005US20050054620 Antiproliferative agents; synergistic mixture with anticancer agents
03/10/2005US20050054607 Reaction product of drug, spacer and vitamin b12; drug delivery
03/10/2005US20050054589 Method for treating diseases using HSP90-inhibiting agents in combination with antibiotics
03/10/2005US20050054012 Using homeobox repeat sequences as tool in detection and treatment of facial muscular disorders
03/10/2005US20050053977 Methods for treating lentivirus infections
03/10/2005US20050053958 Using allelic variation in breast cancer genes (BRCA) as diagnostic tool in detection of mammary gland cell proliferative disorders
03/10/2005US20050053667 a hydrogel polymer; an immunogen encapsulated in said hydrogel particle; a ligand on a surface of hydrogel particle, interacts with an antigen presenting cell and providing an activation signal to antigen presenting cell
03/10/2005US20050053627 Vaccines for Mycoplasma bovis and methods of use
03/10/2005US20050053598 Immunoglobulin formulation and method of preparation thereof
03/10/2005US20050053553 Combined doses of formoterol and fluticasone
03/10/2005CA2824106A1 Compound capable of binding s1p receptor and pharmaceutical use thereof
03/10/2005CA2542372A1 Method of promoting graft survival with anti-tissue factor antibodies
03/10/2005CA2537928A1 Method of treatment and bioassay involving macrophage migration inhibitory factor (mif) as cardiac-derived myocardial depressant factor
03/10/2005CA2537459A1 Formulation of a mixture of free-b-ring flavonoids and flavans for use in the prevention and treatment of cognitive decline and age-related memory impairments
03/10/2005CA2537119A1 Ophthalmic compositions for treating ocular hypertension
03/10/2005CA2537093A1 Compound capable of binding s1p receptor and pharmaceutical use thereof
03/10/2005CA2536955A1 Silver dihydrogen citrate compositions comprising a second antimicrobial agent
03/10/2005CA2536947A1 Echogenic coatings
03/10/2005CA2536910A1 Oral neurotherapeutic cefazolin compositions
03/10/2005CA2536906A1 Compositions for treating pathologies that necessitate suppression of gastric acid secretion
03/10/2005CA2536675A1 A rapid way to obtain high expression clones of mammalian cells using a methylcellulose and immunoprecipitation screening method
03/10/2005CA2536582A1 Intranasal opioid compositions
03/10/2005CA2536454A1 Ocular drug delivery device
03/10/2005CA2536249A1 Delivery of immune response modifier compounds
03/10/2005CA2536247A1 Cellular depolarization and regulation of matrix metalloproteinases
03/10/2005CA2535902A1 Uses of spatial configuration to modulate protein function
03/10/2005CA2535522A1 Fsh glycosylation mutant
03/10/2005CA2533379A1 Monoclonal antibodies against ricin toxin and methods of making and using thereof
03/09/2005EP1511851A2 Method for identification of biologically active agents
03/09/2005EP1511811A2 Oil-soluble pigment compositions
03/09/2005EP1511727A2 Aromatic sulfones and their medical use
03/09/2005EP1162959B1 Pharmaceutical compositions comprising cyclic glycerophosphates and analogs thereof for promoting neural cell differentiation
03/09/2005EP0831847B1 Method of synthesis of di-beta-d-glucopyranosylamine compounds for controlling inflammatory reactions
03/09/2005CN1589906A New oral formulation for 5-HT4 agonists or antagonists
03/09/2005CN1192021C 3-azabicyclo [3.1.0] hexane derivatives as opiate receptors ligands
03/09/2005CN1192011C Calcium receptor-active arylalkyl amines
03/09/2005CN1191852C Vaccine
03/08/2005US6864370 From codeine; oxidation, enolization
03/08/2005US6864274 Allantoin-containing skin cream
03/08/2005US6863865 Sterilization of pharmaceuticals
03/08/2005US6863698 Agent for dyeing keratin containing fibers
03/03/2005WO2005018580A2 Anti-cancer virus desensitization method
03/03/2005WO2005018579A2 Enzymatic processes for the production of 4-substituted 3-hydroxybutyric acid derivatives and vicinal cyano, hydroxy substituted carboxylic acid esters
03/03/2005WO2005018578A2 Method of treating cancer with hdac inhibitors
03/03/2005WO2005018577A2 11-deoxy-6,9-ether erythromycin compounds
03/03/2005WO2005018576A2 N-desmethyl-n-substituted-11-deoxyerythromycin compounds
03/03/2005WO2005018575A2 Estrogen receptor modulators and uses thereof
03/03/2005WO2005018574A2 Immunostimulatory combinations and treatments
03/03/2005WO2005018573A2 6-cycloamino-2-quinolinone derivatives as androgen receptor modulator compounds
03/03/2005WO2005018571A2 Compositions and methods for treating inflammatory lung disease
03/03/2005WO2005018570A2 Optimization of impedance signals for closed loop programming of cardiac resynchronization therapy devices
03/03/2005WO2005018569A2 Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin modulating agent for the treatment of neoplasia
03/03/2005WO2005018568A2 Inhibitors of cathepsin s
03/03/2005WO2005018567A2 Compounds and compositions for the treatment of diabetes and diabetes-related disorders
03/03/2005WO2005018566A2 Topical delivery system containing colloidal crystalline arrays
03/03/2005WO2005018565A2 Compositions for delivering 5-ht agonists across the oral mucosa and methods of use thereof
03/03/2005WO2005018564A2 Compositions of a cyclooxygenase-2 selective inhibitor and a low-molecular-weight heparin for the treatment of central nervous system damage
03/03/2005WO2005018563A2 Compositions of a cyclooxygenase-2 selective inhibitor and a phosphodiesterase inhibitor for the treatment of ischemic mediated central nervous system disorders or injury
03/03/2005WO2005018562A2 Blockade of mtor to prevent a hormonal adaptive response
03/03/2005WO2005018561A2 Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use
03/03/2005WO2005018560A2 Methods of reducing risk of infection from pathogens
03/03/2005WO2005018557A2 Substituted pyridinones
03/03/2005WO2005018556A2 Hydroxylamine substituted imidazo-containing compounds
03/03/2005WO2005018555A2 Lipid-modified immune response modifiers
03/03/2005WO2005018552A2 Heparin binding proteins: sensors for heparin detection
03/03/2005WO2005018551A2 Oxime substituted imidazo-containing compounds
03/03/2005WO2005018549A2 Methods and compositions for tissue repair
03/03/2005WO2005018548A2 Building element for constructing a modular substructure
03/03/2005WO2005018547A2 Mitotic kinesin inhibitors
03/03/2005WO2005018546A2 Compositions for diabetes treatment and prophylaxis
03/03/2005WO2005018545A2 Macrocyclic beta-secretase inhibitors for the treatment of alzheimer's disease
03/03/2005WO2005018542A2 Use of lactoferrin in prophylaxis against infection and/or inflammation in immunosuppressed subjects
03/03/2005WO2005018541A2 Cox-2 inhibitor and serotonin modulator for treating cns damage
03/03/2005WO2005018540A2 Compositions containing sertoli cells and myoid cells and use thereof in cellular transplants
03/03/2005WO2005018538A2 Severe acute respiratory syndrome (sars) polypeptides, antibodies to sars polypeptides and the use thereof in diagnostic, vaccination and therapeutic applications
03/03/2005WO2005018537A2 Structure based and combinatorially selected oligonucleoside phosphorothioate and phosphorodithioate aptamer targeting ap-1 transcription factors
03/03/2005WO2005018536A2 Agonist antibodies that specifically bind the glucagon like peptide-1 receptor
03/03/2005WO2005018534A2 Methods and compositions for rna interference
03/03/2005WO2005018532A2 Purine receptor binding compounds
03/03/2005WO2005018531A2 Pharmaceutical compositions, azo-heterocyclic compounds and method for the production and use thereof
03/03/2005WO2005007070A3 Stable pharmaceutical composition
03/03/2005WO2005000218A3 Macrocyclic cyanine and indocyanine bioconjugates provide improved biomedical applications
03/03/2005WO2004110350A3 Compouds and uses thereof in modulating amyloid beta
03/03/2005WO2004108071A3 Targeting polypeptides to the central nervous system
03/03/2005WO2004105695A3 Methods and materials for treating, detecting, and reducing the risk of developing alzheimer’s disease
03/03/2005WO2004103309A3 Immunosuppressant compounds and compositions
03/03/2005WO2004103306A3 Immunosuppressant compounds and compositions
03/03/2005WO2004103300A3 Compositions and methods of treating reduced blood flow to the cns with cox-2 inhibitors and cholinergic agents
03/03/2005WO2004100525A3 System and method for blocking television signal having multiple different content ratings
03/03/2005WO2004098647A3 Claudins’ underexpression as markers of tumor metastasis
03/03/2005WO2004093819A3 Tamper resistant dosage form comprising co-extruded, adverse agent particles and process of making same
03/03/2005WO2004093812A3 Compounds that induce neuronal differentiation in embryonic stem cells
03/03/2005WO2004091536A3 An albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
1 ... 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 ... 295